Cập nhật về thuốc kháng ngưng tập tiểu cầu trong hội chứng vành cấp
Tóm tắt
Cập nhật về thuốc kháng ngưng tập tiểu cầu trong hội chứng vành cấpTài liệu tham khảo
1. Yusufs, Zhao F, Mehta SR, Chrolavicius s, Tognoni G, FoxKK. Eff ects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to aspirin and fi brinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-89.
3. Chen ZM, Jiang LX, Chen YP. Addition of Clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-21.
4. Mehta SR, Bassand JP, Chrolavicius s, et al. Dose comparisons of Clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930-42.
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15.
6. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus Clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297- 309.
7. BonacaMP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-44 e5.
8. Baigent c, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-60.
9. Gurbel PA, Bilden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the eff ect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
10. Bonello L, Armero s, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010; 56:1630-36.
11. PriceMJ,BergerPB, Teirstein PS, et al. Standard- vs high-dose Clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097-105
12. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl JMed 2009; 360: 354-62.
13. Wiviott SD, TrenkD, Frelinger AL, et al. Prasugrel compared with highloangding and maintenance dose clopidogrelinpatientswithplannedpercutaneouscoronaryintervention: the prasugrelin comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116; 2923-32
14. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 130: e344-e426.
15. Hamm CW, Bassand JP, Agewall s, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart /2011; 32:2999-3054.
16. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST- segment elevation. Eur Heart J 2012; 33:2569 - 619.
17. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
18. Mahaff ey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544-54.
19. Boneỉlo L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014; 63: 872-77.
20. Bellemain-Appaix A, O’Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308:2507-16.
21. Bhatt DL, FoxKA, Hacke w, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-17.
22. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug¬eluting stents. N Engl J Med 2014; 371:2155-66.
23. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107-15.
24. Held c, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.JAm Coll Cardiol 2011; 57:672-84.
25. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefi t with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. / Am Coll Cardiol 2012; 60: 388-96.
